Get the Stockscreener App
1.67
18.44%
0.26
Tenaya Therapeutics Inc stock is traded at $1.67, with a volume of 9.29M.
It is up +18.44% in the last 24 hours and down -24.77% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
See More
Previous Close:
$1.41
Open:
$1.398
24h Volume:
9.29M
Relative Volume:
2.26
Market Cap:
$132.30M
Revenue:
-
Net Income/Loss:
$-117.23M
P/E Ratio:
-0.7489
EPS:
-2.23
Net Cash Flow:
$-95.25M
1W Performance:
-39.27%
1M Performance:
-24.77%
6M Performance:
-47.65%
1Y Performance:
-33.73%
1-Day Range:
$1.35
$1.67
1-Week Range:
$0.9867
$2.92
52-Week Range:
$0.9867
$7.01
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
1.67 | 132.30M | 0 | -117.23M | -95.25M | -1.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Tenaya Therapeutics (NASDAQ:TNYA) Earns Buy Rating from Chardan Capital - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Earns “Buy” Rating from HC Wainwright - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages - MarketBeat
Tenaya Therapeutics (NASDAQ: TNYA) Senior Vice President Chihiro Saito Resigns: 8-K Filing - Defense World
Tenaya Therapeutics stock backed by H.C. Wainwright on TN-401 safety and protein expression gains - Investing.com
Tenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from Chardan Capital - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Given "Buy" Rating at HC Wainwright - MarketBeat
Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data - BioSpace
Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Vaxart (NASDAQ:VXRT) - Defense World
Tenaya Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com Canada
Tenaya stock in selloff on gene therapy data (TNYA:NASDAQ) - Seeking Alpha
Tenaya Therapeutics announces executive departure - Investing.com
Tenaya Therapeutics stock hits 52-week low at $1.49 - Investing.com
Tenaya Therapeutics Reports Promising TN-201 Trial Results - TipRanks
Tenaya Therapeutics’ Senior VP Resigns for New Opportunity - TipRanks
Tenaya reports positive early data on heart gene therapy - Investing.com
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - The Manila Times
Tenaya Therapeutics to Unveil Groundbreaking Gene Therapy Data for Heart Disease Treatment - StockTitan
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire
Fmr LLC Raises Stock Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics' SWOT analysis: gene therapy stock faces pivotal catalysts - Investing.com
Jacobs Levy Equity Management Inc. Buys 226,466 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stake Decreased by RA Capital Management L.P. - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Update - MarketBeat
Around the Helix: Cell and Gene Therapy Company Updates – November 27, 2024 - CGTLive™
First Patient Dosed in RIDGE-1 Trial for Tenaya’s ARV Cardiomyopathy Gene Therapy TN-401 - CGTLive™
Tenaya shares retain Buy rating, price target on trial update - Investing.com
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase - GlobeNewswire
Tenaya Therapeutics Launches First-Ever PKP2-ARVC Gene Therapy Trial, Doses Initial Patient | TNYA Stock News - StockTitan
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $14.75 Average Target Price from Brokerages - MarketBeat
Tenaya Therapeutics Reports Q3 2024 Progress and Financial Results - TipRanks
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Tenaya Therapeutics Issues Stock Options to New Employees at $1.97 Per Share | TNYA Stock News - StockTitan
Tenaya Therapeutics SVP sells $4,786 in stock By Investing.com - Investing.com UK
Tenaya Therapeutics SVP sells $4,786 in stock - Investing.com
RA Capital Management's Strategic Acquisition in Tenaya Therapeu - GuruFocus.com
Research Analysts Offer Predictions for TNYA FY2024 Earnings - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for TNYA Earnings - MarketBeat
William Blair Brokers Increase Earnings Estimates for TNYA - MarketBeat
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) large institutional owners must be happy as stock continues to impress, up 42% over the past week - Simply Wall St
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan Capital - MarketBeat
Latham Group, Inc. to Participate in the Baird 2024 Global Industrial Conference - The Manila Times
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
abrdn plc Invests $1.06 Million in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenaya Therapeutics Inc Stock (TNYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saito Chihiro | SVP, Accounting and Fin. Ops. |
Aug 16 '24 |
Sale |
2.89 |
2,363 |
6,840 |
63,241 |
| Tingley Whittemore | Chief Medical Officer |
Aug 16 '24 |
Sale |
2.89 |
7,428 |
21,500 |
107,106 |
| Ali Faraz | Chief Executive Officer |
Aug 16 '24 |
Sale |
2.89 |
9,748 |
28,216 |
188,331 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):